
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
>ChicagoCombination drug therapy for benign prostatic hyperplasiahas won the endorsement of the American Urological Association in the organization'sfirst-ever clinical guidelines for the management of BPH.





